{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Frationale-for-targeting-her3-in-nsclc-615H5ddp","width":444,"version":"1.0","type":"rich","title":"Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/9900b4eb-ea9f-4202-911e-962f0bc52bbb/lung-her3-prp7140-pod772-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/f8abb744-47a9-4967-9271-298a22b41401\" height=\"200\" width=\"100%\" title=\"Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast, Helena Yu, MD, discusses recent advances in the field of antibody–drug conjugates and the current rationale for targeting HER3 for treatment of non-small-cell lung cancer."}